Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jul 2;14(1):15083.
doi: 10.1038/s41598-024-64175-5.

Impact of baseline ECG characteristics on changes in cardiac biomarkers and echocardiographic metrices after acute myocardial infarction treated with Empagliflozin

Martin Benedikt  1 , Faisal Aziz  2   3 , Thomas Fröschl  1 , Christoph Strohhofer  1 , Ewald Kolesnik  1 , Norbert Tripolt  2   3 , Peter Pferschy  2   3 , Markus Wallner  1 , Heiko Bugger  1 , Andreas Zirlik  1 , Daniel Scherr  1 , Harald Sourij #  2   3 , Dirk von Lewinski #  4
Affiliations
Randomized Controlled Trial

Impact of baseline ECG characteristics on changes in cardiac biomarkers and echocardiographic metrices after acute myocardial infarction treated with Empagliflozin

Martin Benedikt et al. Sci Rep. .

Abstract

The EMMY trial was a multicentre, investigator-initiated, placebo-controlled, double-blind trial, which enrolled 476 patients immediately following AMI and the first study demonstrating a significant reduction in NT-proBNP-levels as well as significant improvements in cardiac structure and function in patients after acute myocardial infarction treated with empagliflozin vs. placebo. However, hardly any data are available investigating the prognostic role of baseline electrocardiogram metrics in SGLT2-inhibitor-treated patients. This post-hoc analysis investigated the association of baseline ECG metrics collected in one centre of the trial (181 patients) with changes in structural and functional cardiac parameters as well as cardiac biomarkers in response to Empagliflozin treatment. A total of 181 patients (146 men; mean age 58 ± 14 years) were included. Median PQ-interval was 156 (IQR 144-174) milliseconds (ms), QRS width 92 (84-98) ms, QTc interval 453 (428-478) ms, Q-wave duration 45 (40-60) ms, Q-wave amplitude 0.40 (0.30-0.70) millivolt (mV), and heart rate was 71 (64-85) bpm. For functional cardiac parameters (LVEF and E/e') of the entire cohort, a greater decrease of E/e' from baseline to week 26 was observed in shorter QRS width (P = 0.005).Structural cardiac endpoints were only found to have a significant positive correlation between LVEDD and Q wave duration (P = 0.037). Higher heart rate was significantly correlated with better response in LVEF (P = 0.001), E/e' (P = 0.021), and NT-proBNP (P = 0.005). Empagliflozin-treatment showed no interaction with the results. Baseline ECG characteristics post AMI are neither predictive for beneficial NTproBNP effects of Empagliflozin post AMI, nor for functional or structural changes within 26 weeks post AMI.

Keywords: Electric conduction; Electrocardiogram; Empagliflozin; Heart failure; Myocardial infarction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Consort diagram of EMMY and the ECG sub-analysis.
Figure 2
Figure 2
Correlation plots of QRS width (in ms) with NTproBNP and LVEF at week 26.
See this image and copyright information in PMC

References

    1. McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 2019;381:1995–2008. doi: 10.1056/NEJMoa1911303. - DOI - PubMed
    1. Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 2020;383:1413–1424. doi: 10.1056/NEJMoa2022190. - DOI - PubMed
    1. Zannad F, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet. 2020;396:819–829. doi: 10.1016/S0140-6736(20)31824-9. - DOI - PubMed
    1. Anker SD, et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 2021;385:1451–1461. doi: 10.1056/NEJMoa2107038. - DOI - PubMed
    1. Solomon SD, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 2022 doi: 10.1056/NEJMoa2206286. - DOI - PubMed

Publication types